Unknown

Dataset Information

0

Study Characteristics and Risk of Bias of Clinical Trials Supporting FDA Approval of Cardiovascular Drugs, 2006-2020.

ABSTRACT:

SUBMITTER: Shu M 

PROVIDER: S-EPMC9411468 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Study Characteristics and Risk of Bias of Clinical Trials Supporting FDA Approval of Cardiovascular Drugs, 2006-2020.

Shu Meijun M   Chen Siliang S   Li Jiarui J  

Journal of general internal medicine 20211026 11

Similar Datasets

Unknown Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020.
| S-EPMC7988366 | biostudies-literature
Unknown Characteristics of Trials Preceding FDA Approval of Novel Psychiatric Drugs.
| S-EPMC11774090 | biostudies-literature
Unknown Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies.
| S-EPMC7860639 | biostudies-literature
Unknown Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
| S-EPMC6199729 | biostudies-literature
Unknown Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
| S-EPMC9856662 | biostudies-literature
Unknown Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapies.
| S-EPMC12258628 | biostudies-literature
Unknown ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.
| S-EPMC5028264 | biostudies-literature
Unknown Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.
| S-EPMC8881772 | biostudies-literature
Unknown Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.
| S-EPMC11392992 | biostudies-literature
Unknown Feasibility of Emulating Clinical Trials Supporting US FDA Supplemental Indication Approvals of Drugs and Biologics.
| S-EPMC10546285 | biostudies-literature